AMERICAN SHARED HOSPITAL SERVICES (AMEX:AMS), a leading provider
of turnkey technology solutions for advanced radiosurgical and radiation
therapy services, today shared a recent announcement from Mevion Medical
Systems, Inc., formerly Still River Systems, Inc., regarding Mevion
Medical Systems Receipt of CE Marking Certification for its MEVION S250
Proton Therapy System. AMS owns approximately 1% of Mevion. AMS is
developing proton therapy centers in Boston, Orlando and Long Beach,
California, which are expected to employ the MEVION S250 proton therapy
device. The MEVION S250 is currently pending FDA 510(k).
Mevion Medical Systems Receives CE Marking Certification
for
the MEVION S250 Proton Therapy System
LITTLETON, MA, Mar. 14, 2012 -- Mevion Medical Systems, a
radiation therapy company dedicated to advancing the treatment of
cancer, has announced today that it has received CE Marking
certification for the MEVION S250 Proton Therapy System. This important
commercial milestone indicates that Mevion has completed its development
in compliance with the European Union's Medical Device Directive. The CE
Marking allows the MEVION S250 to be marketed, sold, and installed in
the European Union and in any country recognizing CE Mark approval.
Proton beam radiotherapy can accurately deliver targeted radiation doses
with complete proton energy absorption at predictable tissue depth, thus
allowing precise radiation delivery adjacent to critical structures and
lower radiation doses to healthy structures. The availability of proton
therapy has remained very limited however, due to the enormous cost,
large footprint, and technical complexity of traditional proton therapy
systems.
CE Marking of the MEVION S250 gives hospitals and cancer treatment
centers throughout the European Union, and other regions where CE
Marking is recognized, the ability to order, install, and treat patients
with this revolutionary medical device. Powered by a TriNiobium CoreTM,
the MEVION S250 significantly reduces the cost, size and complexity of
proton therapy systems to levels similar to modern X-ray radiation
therapy devices, and brings accessibility, affordability and
practicality to proton therapy. "We are very pleased to receive CE
Marking certification for the MEVION S250, the final step to offer this
first of its kind proton therapy system to healthcare providers and
patients in the European Union," said Joseph K. Jachinowski, Chief
Executive Officer.